These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 38142645)

  • 21. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioassay Development for Bispecific Antibodies-Challenges and Opportunities.
    Register AC; Tarighat SS; Lee HY
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific and bifunctional single chain recombinant antibodies.
    Kriangkum J; Xu B; Nagata LP; Fulton RE; Suresh MR
    Biomol Eng; 2001 Sep; 18(2):31-40. PubMed ID: 11535414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Functionalization of Bispecific Therapeutic Antibodies Based on Protein Engineering].
    Asano R; Kumagai I
    Yakugaku Zasshi; 2015; 135(7):851-6. PubMed ID: 26135084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics.
    Choi SH; Shah K
    Discov Med; 2016 Sep; 22(120):157-166. PubMed ID: 27755970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
    Guo X; Wu Y; Xue Y; Xie N; Shen G
    Front Immunol; 2023; 14():1291836. PubMed ID: 38106416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges.
    Du Y; Xu J
    Adv Mater; 2021 Dec; 33(48):e2103114. PubMed ID: 34585802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
    Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.
    Van Blarcom T; Lindquist K; Melton Z; Cheung WL; Wagstrom C; McDonough D; Valle Oseguera C; Ding S; Rossi A; Potluri S; Sundar P; Pitts S; Sirota M; Galindo Casas M; Yan Y; Jones J; Roe-Zurz Z; Srivatsa Srinivasan S; Zhai W; Pons J; Rajpal A; Chaparro-Riggers J
    MAbs; 2018; 10(2):256-268. PubMed ID: 29227213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential therapeutic roles for antibody mixtures.
    Raju TS; Strohl WR
    Expert Opin Biol Ther; 2013 Oct; 13(10):1347-52. PubMed ID: 23886377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intein mediated high throughput screening for bispecific antibodies.
    Hofmann T; Schmidt J; Ciesielski E; Becker S; Rysiok T; Schütte M; Toleikis L; Kolmar H; Doerner A
    MAbs; 2020; 12(1):1731938. PubMed ID: 32151188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    Parren PW; Burton DR; Bradbury A; Huston JS; Carter PJ; Veldman T; Chester KA; Larrick JW; Alfenito MR; Scott JK; Weiner LM; Adams GP; Reichert JM
    MAbs; 2015; 7(6):981-8. PubMed ID: 26421752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
    Zhu H; Wang J; Zhang Q; Pan X; Zhang J
    Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins.
    Surowka M; Schaefer W; Klein C
    MAbs; 2021; 13(1):1967714. PubMed ID: 34491877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2023 Mar; 28(3):103462. PubMed ID: 36464142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.